Literature DB >> 2476934

Abnormalities of pathways of fibrin turnover in lung lavage of rats with oleic acid and bleomycin-induced lung injury support alveolar fibrin deposition.

S Idell1, K K James, C Gillies, D S Fair, R S Thrall.   

Abstract

Alveolar fibrin deposition commonly accompanies acute lung injury, but the nature of the local abnormalities of coagulation and fibrinolysis that support pathologic fibrin deposition are not well understood. The trended abnormalities of procoagulant and fibrinolytic activities occurring in lung lavage fluids of Fischer 344 rats after lung injury induced by intravenous oleic acid (OA) or intratracheal bleomycin were studied. After injury by either agent, bronchoalveolar lavage (BAL) contained increased procoagulant activity and decreased fibrinolytic activity. Lavage procoagulant activity was mainly due to an activator of Factor X attributable to the extrinsic coagulation pathway, and fibrinolytic activity was almost completely plasminogen dependent. Major mechanisms of inhibition of fibrinolytic activity involved both the inhibition of the plasminogen activator (PA) and plasmin. These abnormalities were temporally associated with prominent alveolar fibrin deposition in both models. In OA-treated animals, lavage fibrinolytic activity was absent or profoundly decreased, and antiplasmin and procoagulant activities were increased within 4 hours after the induction of acute lung injury. By 24 hours after OA, lavage PA inhibitor (PAI) activity was elevated with sustained antiplasmin activity. By 3 days after OA, these abnormalities had resolved in association with almost complete resolution of alveolar fibrin deposits. Within 3 days after bleomycin-induced lung injury, lavage procoagulant activity was increased and fibrinolytic activity was depressed due to increased antiplasmin and PAI activities. These conditions persisted for 2 weeks, during which time alveolar fibrin deposition was associated with the development of pulmonary fibrosis. These data indicate that a disruption of the normal balance between procoagulant and fibrinolytic activities occurs in alveolar lining fluids of rats with alveolitis induced by either OA or bleomycin, and that concurrent abnormalities of pathways of fibrin turnover that occur in alveolar lining fluids promote the alveolar fibrin deposition associated with these lung injuries.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2476934      PMCID: PMC1879916     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  32 in total

1.  Effects of fibrinogen derivatives upon the inflammatory response. Studies with human fibrinopeptide B.

Authors:  R M Senior; W F Skogen; G L Griffin; G D Wilner
Journal:  J Clin Invest       Date:  1986-03       Impact factor: 14.808

2.  Bronchoalveolar lavage procoagulant activity in bleomycin-induced lung injury in marmosets. Characterization and relationship to fibrin deposition and fibrosis.

Authors:  S Idell; K K Gonzalez; C K MacArthur; C Gillies; P N Walsh; J McLarty; R S Thrall
Journal:  Am Rev Respir Dis       Date:  1987-07

3.  Local abnormalities of coagulation and fibrinolysis and alveolar fibrin deposition in sheep with oleic acid-induced lung injury.

Authors:  S Idell; B T Peterson; K K Gonzalez; L D Gray; R Bach; J McLarty; D S Fair
Journal:  Am Rev Respir Dis       Date:  1988-11

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Procoagulant activity in bronchoalveolar lavage in the adult respiratory distress syndrome. Contribution of tissue factor associated with factor VII.

Authors:  S Idell; K Gonzalez; H Bradford; C K MacArthur; A M Fein; R J Maunder; J G Garcia; D E Griffith; J Weiland; T R Martin
Journal:  Am Rev Respir Dis       Date:  1987-12

6.  Macrophage migration in fibrin gel matrices.

Authors:  P S Ciano; R B Colvin; A M Dvorak; J McDonagh; H F Dvorak
Journal:  Lab Invest       Date:  1986-01       Impact factor: 5.662

7.  Tissue fibrin deposition during acute lung injury in rabbits and its relationship to local expression of procoagulant and fibrinolytic activities.

Authors:  R G Sitrin; P G Brubaker; J C Fantone
Journal:  Am Rev Respir Dis       Date:  1987-04

8.  Intraluminal fibrosis in interstitial lung disorders.

Authors:  F Basset; V J Ferrans; P Soler; T Takemura; Y Fukuda; R G Crystal
Journal:  Am J Pathol       Date:  1986-03       Impact factor: 4.307

9.  Effect of corticosteroids on lung volume-pressure curves in bleomycin-induced lung injury in the rat.

Authors:  M F Grunze; D Parkinson; S B Sulavik; R S Thrall
Journal:  Exp Lung Res       Date:  1988       Impact factor: 2.459

10.  Disorganization of cultured vascular endothelial cell monolayers by fibrinogen fragment D.

Authors:  C V Dang; W R Bell; D Kaiser; A Wong
Journal:  Science       Date:  1985-03-22       Impact factor: 47.728

View more
  16 in total

1.  Urokinase Plasminogen Activator Overexpression Reverses Established Lung Fibrosis.

Authors:  Jeffrey C Horowitz; Daniel J Tschumperlin; Kevin K Kim; John J Osterholzer; Natalya Subbotina; Iyabode O Ajayi; Seagal Teitz-Tennenbaum; Ammara Virk; Megan Dotson; Fei Liu; Delphine Sicard; Shijing Jia; Thomas H Sisson
Journal:  Thromb Haemost       Date:  2019-11-08       Impact factor: 5.249

2.  PAI-1 promotes the accumulation of exudate macrophages and worsens pulmonary fibrosis following type II alveolar epithelial cell injury.

Authors:  John J Osterholzer; Paul J Christensen; Vibha Lama; Jeffrey C Horowitz; Noboru Hattori; Natalya Subbotina; Andrew Cunningham; Yujing Lin; Benjamin J Murdock; Roger E Morey; Michal A Olszewski; Daniel A Lawrence; Richard H Simon; Thomas H Sisson
Journal:  J Pathol       Date:  2012-06-06       Impact factor: 7.996

3.  Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice.

Authors:  N Hattori; J L Degen; T H Sisson; H Liu; B B Moore; R G Pandrangi; R H Simon; A F Drew
Journal:  J Clin Invest       Date:  2000-12       Impact factor: 14.808

4.  Thrombin-activatable fibrinolysis inhibitor deficiency attenuates bleomycin-induced lung fibrosis.

Authors:  Hajime Fujimoto; Esteban C Gabazza; Osamu Taguchi; Yoichi Nishii; Hiroki Nakahara; Nelson E Bruno; Corina N D'Alessandro-Gabazza; Michael Kasper; Yutaka Yano; Mariko Nagashima; John Morser; George J Broze; Koji Suzuki; Yukihiko Adachi
Journal:  Am J Pathol       Date:  2006-04       Impact factor: 4.307

5.  The development of bleomycin-induced pulmonary fibrosis in mice deficient for components of the fibrinolytic system.

Authors:  C M Swaisgood; E L French; C Noga; R H Simon; V A Ploplis
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

6.  Bronchoconstrictor effect of thrombin and thrombin receptor activating peptide in guinea-pigs in vivo.

Authors:  C Cicala; M Bucci; G De Dominicis; P Harriot; L Sorrentino; G Cirino
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

7.  Changes in procoagulant and fibrinolytic gene expression during bleomycin-induced lung injury in the mouse.

Authors:  M A Olman; N Mackman; C L Gladson; K M Moser; D J Loskutoff
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

8.  Low anticoagulant heparin blocks thrombin-induced endothelial permeability in a PAR-dependent manner.

Authors:  Joyce N Gonzales; Kyung-mi Kim; Marina A Zemskova; Ruslan Rafikov; Brenten Heeke; Matthew N Varn; Stephen Black; Thomas P Kennedy; Alexander D Verin; Evgeny A Zemskov
Journal:  Vascul Pharmacol       Date:  2014-01-25       Impact factor: 5.773

9.  Fibrosing vasculitis in Wegener's granulomatosis: ultrastructural and immunohistochemical analysis of the vascular lesions.

Authors:  D Gindre; S Peyrol; M Raccurt; P Sommer; R Loire; J A Grimaud; J F Cordier
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

10.  Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene.

Authors:  D T Eitzman; R D McCoy; X Zheng; W P Fay; T Shen; D Ginsburg; R H Simon
Journal:  J Clin Invest       Date:  1996-01-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.